EUCTR2005-004966-17-SE进行中（未招募）不适用
PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension - EMBH
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 153
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Are men and women =18 and =70 years of age.
- •[2] Have given signed informed consent to participate in this study.
- •[3] Are diagnosed with mild essential hypertension at screening (currently untreated or treated with monotherapy)
- •CBPM range for untreated patients is SBP 140 to 159 mm Hg and/or DBP 90 to 99 mm Hg.
- •CBPM range for patients on antihypertensive monotherapy is SBP 130 to 150 mm Hg and/or DBP 85 to 95 mm Hg.
- •[4] Have two mean CBPM (calculated using the last two of three readings) (SBP 140 to 159 mm Hg and/or DBP 90 to 99 mm Hg) during Study Period 2 (use mean CBPM readings from either of the following: Visit 2 and Visit 4 OR Visit 3 and Visit 4).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[5] Are investigator site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- •[6] Are Lilly employees.
- •[7] Have planned or are likely to require major surgery during the course of the study.
- •[8] Have any other medical condition, laboratory abnormality, or circumstance prior to randomization, which, in the opinion of the investigator, could affect patient safety, preclude evaluation of response on similar activity days throughout the trial, prohibit the ability to comply with study procedures and restrictions, or completion of the study (for example, swing-shift working conditions).
- •[9] Women of child-bearing potential who do not agree to use a reliable method of birth control (for example, use of oral contraceptives or Norplant; diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) during the study and for 1 month following the last dose of study drug.
- •[10] Pregnant or nursing women. Women not surgically sterilized and between menarche and 1 year post menopause must test negative for pregnancy at the time of enrollment based on a serum pregnancy test.
- •[11] Are unable, unreliable, and/or unwilling to provide informed consent, make themselves available for the duration of the study, or will not abide by the procedures and study restrictions.
- •[12] Have any other condition, which in the opinion of the investigator, precludes the patient from providing informed consent, following the protocol procedures and restrictions, or completing the protocol.
- •[13] Have secondary or malignant hypertension.
- •[14] Have or have had a history of hyperlipidemia within 3 months of screening requiring treatment according to ESH/ESC guidelines (ESH-ESC 2003).
- •[15] Have any previous CV disease other than hypertension.
- •[16] Have type 1 or 2 diabetes mellitus.
- •[17] Have a body mass index (BMI) >35 kg/m2.
- •[18] Have a history of symptomatic postural hypotension or postural dizziness.
- •[19] Patient-reported history of human immunodeficiency virus (HIV) infection.
- •[20] Have or have had a history of a chronic muscular or neuromuscular disease, including a history of prior rhabdomyolysis, drug-induced myopathy (for example, statin or fibric acid), or an unexplained elevation in CK = 3 x ULN.
- •[21] Are currently under suspicion of having cancer or have had a history of cancer in the past 2 years, with the exception of excised superficial lesions such as basal cell carcinoma and squamous cell carcinoma of the skin.
- •[22] Have chronic alcohol or drug abuse or dependency.
- •[23] Currently adhering to, have used within 2 months prior to screening, or have plans to adopt diets with aggressive carbohydrate restrictions for weight loss, such as, but not limited to, Atkins or South Beach diets.
- •[24] Currently use, have used within 2 months prior to screening, or plan to use during the trial period dietary supplements or over the counter formulations intended for weight loss.
- •[25] Have active hepatobiliary disease, serologic evidence of past or active hepatitis B or C, or active gallbladder disease.
- •[26] Liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], or total bilirubin >1.5x the upper limit of normal [ULN]).
研究者
相似试验
终止
2 期
A clinical research study testing olaparib, in Homologous recombination (HR) deficient metastatic breast and relapsed ovarian cancer in patients who do not have hereditary mutations in BReast CAncer susceptibility gene 1 and gene 2 (BRCA1 and BRCA2)ACTRN12617000855325niversity of Sydney22
已完成
2 期
A Study in People With High CholesterolHypercholesterolemiaNCT00133380Eli Lilly and Company300
已完成
不适用
The effect of selective PPAR-alpha modulator to Non alcoholic fatty liver disease with dyslipidemia.on alcoholic fatty liver diseaseJPRN-UMIN000037615Kyoto Prefectural University of Medicine20
终止
2 期
Cemdisiran and eculizumab dose-ranging study for paroxysmal nocturnal haemoglobinuriaParoxysmal nocturnal haemoglobinuria (PNH)Haematological DisordersParoxysmal nocturnal haemoglobinuria [Marchiafava-Micheli]ISRCTN31882639niversity of Leeds9
尚未招募
2 期
Evaluating a new drug (AUY922) for controlling prostate cancer cell growth using laboratory based outcomes in men with high risk prostate cancerCancer - ProstateProstate CancerACTRN12614000789662The University of Sydney55